Announcements Trials
Browse Landscape

Phase

Phase 2 82Phase 3 18Phase 1/2 17Phase 1 16Phase NA 5Phase 2/3 3Phase EARLY_PHASE1 2

Status

Completed 11Withdrawn 5Unknown 5Active not recruiting 5Terminated 3Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 2Vipoma 1Somatostatinoma 1Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Carboplatin 9Paclitaxel 8Gemcitabine 8Cisplatin 8Cyclophosphamide 7Fluorouracil 6Docetaxel 5Capecitabine 5Granulocyte Colony-Stimulating Factor 4Etoposide 4Vinorelbine 3Stem Cell Transplantation 3Radiotherapy 3Pemetrexed 3Melphalan 3Leucovorin 3Filgrastim 3Erlotinib Hydrochloride 3Bone Marrow Transplantation 3Bevacizumab 3umbralisib 2ublituximab 2pembrolizumab 2peginterferon alfa-2b 2fludarabine 2Whole-Body Irradiation 2Trastuzumab 2Transplantation, Homologous 2Surveys and Questionnaires 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Leucovorin × Clear all
NCT05171166 2025-12-18

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Peking University

Phase 2/3 Terminated
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT02220088 2019-01-11

The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial

Sun Yat-sen University

Phase 2/3 Terminated
79 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡